AstraZeneca falls as FDA advisers reject breast cancer drug use

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 1.9% to 13,688p after the US regulator's advisory panel declined to back ...
MassDevice

Philips gets FDA clearance for flexible MR coil

Philips (NYSE:PHG) announced that it received FDA 510(k) clearance for its Smart Fit TorsoCardiac magnetic resonance (MR) ...
Medscape

FDA OKs First Non-Antipsychotic for Alzheimer’s Agitation

The FDA has approved Auvelity for AD agitation. The combination of dextromethorphan and bupropion is the first oral non-antipsychotic approved for this indication.

Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Approval of AUVELITY (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...
MyJoyOnline

“This Advert Is FDA-Approved” – Unpacking the FDA tagline: What consumers need to know

The Food and Drugs Authority (FDA) is one of the national bodies responsible for protecting public health in Ghana. It ...

Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1

Belite Bio (NASDAQ: BLTE) is one of the best up and coming stocks with highest upside potential. On April 21, Belite Bio ...
pharmaphorum

Axsome breaks new ground in Alzheimer's with Auvelity OK

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...
Emirates 24/7

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

AstraZeneca shares fell nearly 2% on Friday after a U.S. Food and Drug Administration advisory panel voted overnight against ...